Rufinamide for pediatric patients with Lennox-Gastaut syndrome: A comprehensive overview

Pediatric Drugs

Volumn 13, Issue 2, 2011, Pages 97-106

  Wier, Heather Ann ^a   Cerna, Ana ^b   So, Tsz Yin ^a  

^a Moses H Cone Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBOXYLESTERASE; CGP 47292; CLOBAZAM; CLONAZEPAM; DRUG METABOLITE; ETHINYLESTRADIOL; FELBAMATE; LAMOTRIGINE; NORETHISTERONE; ORA PLUS; ORA SWEET; ORA SWEET SF; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; SODIUM CHANNEL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ACTION POTENTIAL; ADD ON THERAPY; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; AREA UNDER THE CURVE; ATONIC SEIZURE; COGNITIVE DEFECT; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EPILEPSY; EPILEPTIC FOCUS; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; HOSPITALIZED CHILD; HUMAN; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYOCLONUS SEIZURE; NAUSEA; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RECEPTOR BLOCKING; REFRACTORY EPILEPSY; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; STEVENS JOHNSON SYNDROME; SUSPENSION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TONIC CLONIC SEIZURE; URINARY EXCRETION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; CHILD; EPILEPSIES, PARTIAL; HUMANS; MENTAL RETARDATION; SPASMS, INFANTILE; TREATMENT OUTCOME; TRIAZOLES;

EID: 79952126763     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11586920-000000000-00000     Document Type: Review

References (32)

1. Hancock EC, Cross HJ. The treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; (3): CD003277
2. Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs 2010; 24 (5): 363-74
3. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol 2003; 20 (6): 426-41 (Pubitemid 38133970)
4. Lennox WG, Davis JP. Clinical correlates of the fast and the slow spike-wave electroencephalogram. Pediatrics 1950; 5 (4): 626-44
5. Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("epilim"). Dev Med Child Neurol 1977; 19 (1): 9-25 (Pubitemid 8036537)
6. Banzel [package insert]. Woodcliff Lake (NJ): Eisai Inc, 2008
7. McLean MJ, Schmutz M, Pozza M, et al. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 2005; 46 Suppl. 8: 296
8. Bialer M, Johannesen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999; 34 (1): 1-41 (Pubitemid 29130316)
9. Perucca E, Cloyd J, Critchley D, et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49 (7): 1123-41 (Pubitemid 351991401)
10. White HS, Franklin MR, Kupferberg HJ, et al. The anticonvulsant profile of rufinamide (CGP33101) in rodent seizuremodels. Epilepsia 2008; 49 (7): 1213-20 (Pubitemid 351991388)
11. Snead III OC, Banerjee PK, Burnham M, et al. Modulation of absence seizures by the GABA(A) receptor: a critical role for metabotropic glutamate receptor 4 (mGluR4). J Neurosci 2000; 20 (16): 6218-24 (Pubitemid 30658415)
12. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70 (21): 1950-8
13. Sachdeo RC, Rovenfeld WE, Choi L. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia 1998; 39 (6): 166-7
14. Elger CE, Stefan H, Mann A, et al.A24-week multicenter randomized, doubleblind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010; 88 (2-3): 255-63
15. Chang SW, Choi L, Karopheyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 1998; 39 Suppl. 6: S59
16. Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006; 60 (11): 1497-501 (Pubitemid 44560351)
17. Marchand M, Fuseau E, Critchley DJ. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. J Pharmacokinet Pharmacodyn 2010; 37 (1): 99-118
18. Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 20 (9): 751-60 (Pubitemid 44373706)
19. Cheung WK, Kianifard F, Wong A, et al. Intra-and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400 mg suspension. Pharm Res 1995; 12 (12): 1878-82 (Pubitemid 26032294)
20. Cardot JM, Lecaillon JB, Czendlik C, et al. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos 1998; 19: 259-62 (Pubitemid 28218421)
21. Palhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebocontrolled proof of principle trial in patients with epilepsy. Epilepsy Res 2001; 43 (2): 115-24 (Pubitemid 32115522)
22. Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). Eur J Paediatr Neurol 2009; 13 (6): 493-504
23. Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010; 10 (1): 1-6
24. Arroyo S. Rufinamide. Neurotherapeutics 2007; 4 (1): 155-62 (Pubitemid 46107325)
25. Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010; 122 (3): 202-8
26. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010; 17 (4): 546-8
27. Kluger G, Kurdlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy; first European experience. Epilepsy Behav 2009; 14 (3): 491-5
28. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebocontrolled trial. Epilepsia 2009; 50 (8): 1899-909
29. Herman ST. Adopting an orphan drug: rufinamide for Lennox-Gastaut syndrome. Epilepsy Curr 2009; 9 (3): 72-4
30. Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24 (12): 1520-5
31. Hutchinson DJ, Liou Y, Best R, et al. Stability of extemporaneously prepared rufinamide oral suspensions. Ann Pharmacother 2010; 44 (3): 462-5
32. Rufinamide: CGP 33101, E 2080, RUF 331, Xilep. Drugs R D 2005; 6 (4): 249-52